Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 801–900 of 1,002
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers
Drobner, J. C., Doppalapudi, K., Saraiya, B., Packiam, V. T., & Ghodoussipour, S. B. (2024) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.6.078 · Cited by 15
“FMT led to reprogramming of the recipient patients’ tumor microenvironment with increased CD8(+) T cell infiltration and interferon-gamma signaling as well as increased Ruminococcaceae and Bifidobacteriaceae species [26,74].”
BackgroundProfir, M., Roşu, O., Creţoiu, S. M., & Gașpar, B. S. (2024) · Microorganisms · doi:10.3390/microorganisms12050955 · Cited by 12
From mucosal infection to successful cancer immunotherapy
Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00784-5 · Cited by 11
“Moreover, humoral or cellular immune responses directed against a specific panel of commensals residing in the digestive tract are associated with clinical outcome to cancer therapies across different countries and continents 109,114–117 .”
BackgroundExploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis
Liu, Q.-L., Zhou, H., Wang, Z., & Chen, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1563184 · Cited by 14
Feigenberg, S. J., Costabile, F., Tanes, C., Bittinger, K. L., O'Connor, R., Agarwal, D., Skoufos, G., Salaris, S., Hatzigeorgiou, A. G., Κωστόπουλος, Ν., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011356 · Cited by 15
Mechanisms, advances, and challenges of immunotherapy in gastric cancer
Wang, Z., & Wang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639487 · Cited by 11
Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma
Chen, P., Devkota, S., Shiao, S. L., Hendifar, A. E., & Yang, J. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568962 · Cited by 13
Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy
Yan, D., Yu, Y., Liang, C., Cui, Z., Shi, L., Li, G., & Ren, C. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02566-6 · Cited by 12
Wang, X., He, J., Ding, G., Tang, Y., & Wang, Q. (2026) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s572089 · Cited by 13
“33,34 In NSCLC, metagenomic profiling links response to greater abundance of taxa such as Bacteroides (eg, Bacteroides caccae) and Prevotella, whereas antibiotic exposure can reduce microbial diversity and impair ICI efficacy by depleting beneficial taxa or enriching pathways that suppress immunity.”
Tumor exosomes impact functional hallmarks of cancer
Laein, M. H., Thinakaran, Y., Katoueezadeh, M., Iyappan, R., Baker, J., Kalailingam, P., Ngan, S. C., McCarthy, N. E., Klentrou, P., Tsiani, E., et al. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10333-2 · Cited by 13
Du, P., Jing, J., & He, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1091124 · Cited by 15
“The combination of FMT and anti-PD-1 antibody provided clinical benefit in 40% (6/15) of patients and induced rapid microbiota perturbation and TME reprogramming to overcome resistance to anti-PD-1 therapy (Davar et al., 2021).”
BackgroundGut microbiome as a treatment in colorectal cancer
Khan, M., Shah, S., Shah, W., Khan, I., Ali, H., Ali, I., Ullah, R., Wang, X., Mehmood, A., & Wang, Y. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2312294 · Cited by 13
“The gut microbiome may influence the efficacy of immunotherapy by modulating the host immune system [98,99].”
BackgroundSystemic metabolic depletion of gut microbiome undermines responsiveness to melanoma immunotherapy
Zakharevich, N. V., Morozov, M. D., Kanaeva, V. A., Filippov, M. S., Zyubko, T., Ivanov, A. B., Игоревич, У. В., Klimina, K. M., & Olekhnovich, E. I. (2024) · Life Science Alliance · doi:10.26508/lsa.202302480 · Cited by 12
“P 0.001, Davar et al, 2021 adj.”
BackgroundMethodInfluentialMetastasis and the Microbiome: The Impact of Bacteria in Disseminated Colorectal Cancer
Ayabe, R. I., & White, M. G. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904152 · Cited by 14
Microbes in the tumor microenvironment: New additions to break the tumor immunotherapy dilemma
Zhou, L., Fan, S., Zhang, W., Wang, D., & Tang, D. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127777 · Cited by 12
From microbes to medicine: harnessing the gut microbiota to combat prostate cancer
Yadav, A., Kaushik, M., Tiwari, P., & Dada, R. (2024) · Microbial Cell · doi:10.15698/mic2024.05.824 · Cited by 14
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities
Lee, J. B., Huang, Y., Oya, Y., Nützinger, J., Ang, Y. L. E., Sooi, K. W. X., Cho, B. C., & Soo, R. A. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107862 · Cited by 13
Yin, Q., Ni, J., & Ying, J. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1263 · Cited by 13
“115,116 A phase I clinical trial confirms the safety, feasibility, and potential effectiveness of FMT treatment in immunotherapy.”
BackgroundYu, Z., Wang, Q., Wang, Z., Liu, S., Xia, T., Duan, C., Liu, Y., Ding, X., Chen, S., Yu, T., et al. (2024) · Head & Neck · doi:10.1002/hed.27917 · Cited by 14
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
Jalil, A., Donate, M., & Mattei, J. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.54 · Cited by 35
Chen, Y., Wu, J., Cai, K., Xiao, X., Chen, Y., Zhang, X., Deng, S., Pei, C., Chen, Y., Xie, Z., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114283 · Cited by 11
Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy
Grafanaki, K., Maniatis, A., Anastogianni, A., Bania, A., Pasmatzi, E., & Stathopoulos, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124193 · Cited by 14
“The microbiome’s modulatory role in ICI response can be further improved by its modulation using fecal microbiome transplantations from clinical responders or healthy donors [179–181].”
Ecological management of the microbiota in patients with cancer
Xavier, J. B. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01049-3 · Cited by 18
“anti-PD-1 antibodies 105 .”
The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies
Wei, Z., Gao, G., He, Q., Kwok, L. Y., & Sun, Z. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.038 · Cited by 14
“…(FMT) from ICB-responsive patients could reverse resistance in non-responders, and that an increase in bacterial families, such as Ruminococcaceae and Bifidobacteriaceae, in recipients was linked to enhanced immune in filtration in both tumor and gut tissues (NCT03353402, NCT03341143)[116,117].”
Evolution of FMT – From early clinical to standardized treatments
Servetas, S. L., Daschner, P. J., Guyard, C., Thomas, V., Affagard, H., Sergaki, C., Sokol, H., Wargo, J. A., Wu, G. D., & Sabot, P. (2022) · Biologicals · doi:10.1016/j.biologicals.2022.01.004 · Cited by 12
Kamiya, T., & Ohtani, N. (2022) · International Immunology · doi:10.1093/intimm/dxac020 · Cited by 12
Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications
Amara, S., Yang, L. V., Tiriveedhi, V., & Muzaffar, M. (2022) · Cells · doi:10.3390/cells11121900 · Cited by 12
“In this study, Bifidobacterium was associated with a better response to ICIs [10,95].”
BackgroundInfluentialLi, T., Liu, T., Zhao, Z., Pan, Y., Xu, X., Zhang, Y., Zhan, S., Zhou, S., Zhu, W., Guo, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911325 · Cited by 13
“Moreover, transplanting the fecal microbiota from long-term responder melanoma patients to refractory metastatic melanoma patients was found to be able reverse immune resistance to anti-PD-1 immunotherapy and further optimize the efficacy of ICB therapy (41).”
BackgroundRadiation Therapy and the Microbiome; More Than a Gut Feeling
Amit, U., Facciabene, A., & Ben‐Josef, E. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000650 · Cited by 11
“Two recent studies have observed that fecal microbiota transplant improves the antitumor response to checkpoint blockade in otherwise refractory melanoma patients.(48,49) We reported that gut microbiota perturbation by oral vancomycin affects DC antigen presentation and cytokine secretion profile and impacts the outco…”
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity
Yang, L., Li, S., Chen, L., & Zhang, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0241 · Cited by 16
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
Jang, A., Lichterman, J. N., Zhong, J. Y., Shoag, J. E., Garcia, J. A., Zhang, T., & Barata, P. C. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2276629 · Cited by 13
“This has shown remarkable efficacy in refractory metastatic melanoma patients 42,43 and has even been used to treat ICI-induced colitis.”
BackgroundShi, C., Chen, L., Pi, H., Cui, H., Fan, C., Tan, F., Qu, X., Sun, R., Zhao, F., Song, Y., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00500-3 · Cited by 17
“However, the gut microbiome also has a profound effect on immune checkpoint blockade [37 – 39].”
BackgroundTargeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches
Tabolacci, C., Cordella, M., Rossi, S., Bonaccio, M., Eramo, A., Mischiati, C., Beninati, S., Iacoviello, L., Facchiano, A., & Facchiano, F. (2021) · Molecules · doi:10.3390/molecules26123619 · Cited by 12
“Finally, a crucial role of the gut microbiota in the immunomodulation of melanoma patients has recently been demonstrated, with important implications for cancer treatment [56,57].”
BackgroundMakunts, T., Burkhart, K., Abagyan, R. A., & Lee, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263402 · Cited by 10
“Interestingly, in recent studies, fecal microbiota transplants helped overcome PD-1 therapy resistance in melanoma patients [41, 42] where introducing infectious agents improved ICI treatment efficacy, suggesting the infectious agents’ influence on the ICI related immune activation.”
BackgroundChen, Y., & Lai, X. (2022) · Mathematical Biosciences · doi:10.1016/j.mbs.2022.108868 · Cited by 12
Long-read metagenomics for strain tracking after faecal microbiota transplant
Fan, Y., Ni, M., Aggarwala, V., Mead, E. A., Ksiezarek, M., Cao, L., Kamm, M. A., Borody, T. J., Paramsothy, S., Kaakoush, N. O., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02164-8 · Cited by 14
“https://doi.org/10.1038/s41564-025-02164-8 We performed LongTrack to measure the engraftment of donor strains in the recipients, focusing on uncultured strains (Supplementary Tables 7–10).”
InfluentialHuang, H., Peng, S., Liu, Y., Chen, L., & Wu, F. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07885-w · Cited by 11
“Transitional relevance of these findings has been underscored by early-phase clinical studies published in Science , which reported that FMT could overcome PD-1 resistance in melanoma patients [13, 14].”
Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer
Park, U., Heo, J.-Y., Chun, S.-M., Lee, J.-C., Lee, S.-H., & Lee, S.-W. (2026) · Immune Network · doi:10.4110/in.2026.26.e7 · Cited by 11
“Early-phase clinical trials testing FMT from ICB responders into non-responders have shown partial restoration of anti-PD-1 sensitivity (51-53).”
The hallmarks of host-microbiome decoupling
Bautista, J., & López‐Cortés, A. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1801100 · Cited by 11
“…immuno-oncology, together with more consistent associations observed for fiber-rich dietary patterns, illustrate that therapeutic eects may depend more on restoration of functional responsiveness than on microbial replacement alone (Bautista et al., 2025d; Kang and Cai, 2021; Davar et al., 2021).”
Leung, E. L., Huang, J., Zhang, J., Zhang, J., Wang, M., Zhu, Y., Meng, Z., Yu, H., Neher, E., Ma, L., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0243 · Cited by 14
“Interestingly, in patients treated with anti-PD-1 immunotherapy, responders have a relatively high abundance of these bacteria, enhancing the antitumor effect of cytotoxic T cells (Davar et al, 2021; Gopalakrishnan et al, 2018; Routy et al, 2018).”
Rethinking Immune Check Point Inhibitors Use in Liver Transplantation: Implications and Resistance
Ortiz, V., & Loeuillard, E. J. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101407 · Cited by 13
Ebrahimi, R., Masouri, M. M., Khozani, A. A. S. A., Hussein, D. R., & Nejadghaderi, S. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311731 · Cited by 12
Jaeghere, E. A. D., Hamerlinck, H., Tuyaerts, S., Lippens, L., Nuffel, A. M. T. V., Baiden-Amissah, R. E. M., Vuylsteke, P., Henry, S., Trinh, X. B., van Dam, P. A., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.10.020 · Cited by 13
Liu, L., Hao, X., Bai, Y., & Tian, Y. (2024) · Aging Cell · doi:10.1111/acel.14416 · Cited by 20
“…of fecal microbiota transplantation (FMT) and probiotic supplementation has gained traction in disease therapy in human (Baruch et al., 2021 ; Davar et al., 2021 ; Drekonja et al., 2015; Helmink et al., 2019; Ting et al., 2022 ) and also prolonged lifespan in mice (Bárcena et al., 2019;…”
Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy
Bhatnagar, K., Jha, K., Dalal, N., Patki, N., Gupta, G., Kumar, A., Kumar, A., & Chaudhary, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1442788 · Cited by 12
“Additionally, human clinical trials highlighted that in a fraction of FMT recipients, particularly melanoma patients who earlier responded to ICI treatment but later developed ICI-resistance, FMT restored the ICI non-responsiveness (266, 267).”
Laurent, P.-A., André, F., Bobard, A., Deandreis, D., Demaria, S., Depil, S., Eichmüller, S. B., Fernández-Palomo, C., Foijer, F., Galluzzi, L., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2432726 · Cited by 10
Zhuang, L., You, Y., Zeng, S., Yu, Z., Wang, H., Chen, M., & Wen, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1451751 · Cited by 10
“FMT alters the gut microbiota and reprograms the tumor microenvironment to overcome resistance to anti-PD-1 immunotherapy (19).”
Self-citationA conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
Kim, C. Y., Park, D. J., Ahn, B., Baek, S., Hong, M. H., Nguyen, L. T., Hwang, S. H., Kim, N., Podlesny, D., Orakov, A. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55388-3 · Cited by 12
“State-of-the-art research includes clin-icaltrialsdemonstratingthatfecalmicrobiotatransplantation(FMT)to patients can improve therapeutic outcomes 11 – 13 , as well as longitudinal studiesobservingshiftsinthegutmicrobiomecompositionduringICB treatment 14 .”
Precision microbial regulation: Strategies for modulating GIT microbiota for host health
Pei, Z., Li, Q., Zhang, Y., Guo, C., Abdelsattar, M. M., & Bi, Y. (2025) · iMetaOmics. · doi:10.1002/imo2.54 · Cited by 12
“Approaches for the targeted GIT microbiota regulation, such as fecal microbiota transplantation (FMT), synthetic microbial communities (SynComs), genetically engineered microorganisms (GEMs), phages, and nano-materials, have been employed with promising outcomes [13 – 17].”
Cell Death Modalities in Therapy of Melanoma
Wang, M., Zhao, J., Tang, M.-X., Li, M., Zhao, H., Li, Z., & Liu, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083475 · Cited by 11
“Likewise, a study revealed clinical benefits in six out of fifteen previously resistant patients who underwent fecal microbiota transplantation in combination with anti-PD-1 immunotherapy [169].”
Expanding horizons of cancer immunotherapy: hopes and hurdles
Sonar, P. V., Singh, A. K., Mandadi, S., & Sharma, N. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1511560 · Cited by 12
Wu, C., Luo, F., Zhu, Y., Liu, C., Chen, Z., Wang, X., Tan, J., & Liu, Q. (2025) · Exploration · doi:10.1002/exp.20240087 · Cited by 16
Deng, S., Kim, W., Cheng, K., Yang, Q., Singh, Y., Bae, G., Bézière, N., Mager, L. F., Kommoss, S., Sprengel, J., et al. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00391-5 · Cited by 10
“These findings suggest that the gut microbiota’s involvement in ovarian cancer progression may stem from a diverse array of microbial species, each potentially playing a specific role in influencing the tumor microenvironment and disease progression.”
Gut microbiome and colorectal cancer: From pathogenesis to treatment
Lahouty, M., Fadaee, M., Aghaei, R., Alizadeh, F., Jafari, A., & Sharifi, Y. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156034 · Cited by 11
Pamungkas, K. M. N., Dewi, P. I. S. L., Alamsyah, A. Z., Dewi, N. L. P. Y., Dewi, N. N. G. K., Mariadi, I. K., & Sindhughosa, D. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106810 · Cited by 11
Dayhimi, A., Jazi, K., Bigdeli, Y., Farhoudi, F., Erfanimanesh, M., Esmaeili, M., Gorjipour, F., Ajami, M., & Pazoki–Toroudi, H. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251365700 · Cited by 14
“165,208 An imbalance between Bacteroidetes and Firmicutes species negatively impacted responses to PD-1 targeted therapies.”
InfluentialThe Impact of the Host Intestinal Microbiome on Carcinogenesis and the Response to Chemotherapy
Wertman, J. N., Dunn, K. A., & Kulkarni, K. P. (2021) · Future Oncology · doi:10.2217/fon-2021-0087 · Cited by 11
Immunotherapy response-associated Akkermansia: canary in a coal mine?
Cascone, T., Chelvanambi, M., & Wargo, J. A. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.03.007 · Cited by 10
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
Meyo, M. T., Chen, J., Goldwasser, F., Hirsch, L., & Huillard, O. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s263832 · Cited by 13
“A preliminary clinical study has investigated FMT obtained from long-responding melanoma patient as a therapy for anti-PD1 refractory melanoma patients and demonstrated that a single transplantation could help overcome resistance in a subset of patients.(120) A very recent Phase 1 trial showed that a bifidogenic live…”
BackgroundLeardini, D., Venturelli, F., Baccelli, F., Cerasi, S., Muratore, E., Brigidi, P., Pession, A., Prete, A., & Masetti, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315387 · Cited by 12
“This reprogrammed tumor microenvironment did overcome resistance to anti-PD-1 in this subset of PD-1 advanced melanoma [7].”
BackgroundInfluentialVenzel, R., Campos, M. C. P., de Oliveira, L. P., Lins, R. V. D., Siena, Á. D. D., Mesquita, K. T., dos Santos, T. P. M., Nohata, N., Arruda, L. C. M., Sales‐Campos, H., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103988 · Cited by 11
Intratumor microbiota: Occult participants in the microenvironment of multiple myeloma
Zhu, G., Jin, L., Shen, W., Zhao, M., & Liu, N. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188959 · Cited by 11
Personalizing Oncolytic Immunovirotherapy Approaches
Stergiopoulos, G. M., Iankov, I. D., & Galanis, E. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00689-4 · Cited by 10
“Microbiota transplants from responders reprogrammed systemic immunity, favorably changed the TME, and increased immune infiltration to overwhelm primary resistance to anti-PD-1 treatment [172, 173].”
Microbiome modification for personalized treatment of dysbiotic diseases
Sartor, R. B. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.023 · Cited by 10
Sun, L., Ying, J., Guo, R., Jia, L., & Zhang, H. (2024) · Skin Research and Technology · doi:10.1111/srt.70017 · Cited by 9
RetractedChagani, S., & Kwong, L. N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0187 · Cited by 10
Zarour, H. M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.010 · Cited by 10
Self-citationFunayama, E., Hosonuma, M., Tajima, K., Isobe, J., Baba, Y., Murayama, M., Narikawa, Y., Toyoda, H., Tsurui, T., Maruyama, Y., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117749 · Cited by 9
Limeta, A., Gatto, F., Herrgård, M. J., Ji, B., & Nielsen, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.07.032 · Cited by 9
“clinical response and considerable remodeling of the tumor microenvironment [91,92].”
BackgroundKadhim, A. S., & Al-Karawi, A. S. (2023) · American Journal of Bioscience and Bioinformatics · doi:10.54536/ajbb.v2i1.1910 · Cited by 14
“They used multiplex serology to evaluate antibody triggering to 13 H pylori proteins in blood specimens from patients undergoing UBT (Davar et al ., 2021).”
MethodInfluentialGao, X., & Jiang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359029 · Cited by 12
“Interferon-g (IFN-g ) production can be improved by enhancing the biosynthesis of immune-stimulating molecules and metabolites, and oral bi fi dobacterium enhances tumor suppression to the same extent as speci fi c antibody PD-L1 immunotherapy.”
BackgroundPotential of Synbiotics and Probiotics as Chemopreventive Agent
Chin, K. W., Khoo, S. C., Paul, R. P. M., Luang‐In, V., Lam, S. D., & Ling, N. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10299-z · Cited by 12
“It has been shown that FMT improves the effectiveness of anti-programmed death-1 (PD-1) therapy in melanoma patients [132, 133].”
Advances in predictive biomarkers for melanoma immunotherapy
Ma, W., Liu, W., Zhong, J., Zou, Z., Lin, X., Sun, W., Hu, T., Xu, Y., & Chen, Y. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00121-9 · Cited by 13
“High levels of M. restricta and C. albicans, elevated serum LDH, and overweight were linked to increased risk of melanoma progression and poorer response to anti-PD-1 treatment [78].”
Targeting the gut and tumor microbiome in cancer treatment resistance
Čierniková, S., Ševčíková, A., & Mego, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00201.2024 · Cited by 12
Hrubesz, G., Leigh, J., & Ng, T. L. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-14 · Cited by 11
From Gut to Brain: The Impact of Short-Chain Fatty Acids on Brain Cancer
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Sanghvi, G. V., Menon, S. V., Sharma, P., Tomar, B. S., Sharma, A., Sameer, H. N., Hamad, A. K., et al. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08830-8 · Cited by 10
“It is crucial to note that the immune landscape and clinical responses in previous non-responders were positively impacted by microbiota transplantation from initial responders to anti-PD-1 therapy to non-responder patients, collectively referred to as FMT (Baruch et al., 2021; Davar et al., 2021).”
Friends close, enemies closer: the complex role of the microbiome in antitumor immunity
Patra, D., Dev, G., Hand, T. W., & Overacre-Delgoffe, A. E. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102537 · Cited by 11
The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage
L'Orphelin, J. ‐., Dompmartin, A., & Dréno, B. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13224 · Cited by 14
“Fecal microbiome transplantation (FMT) modulates peripheral and intratumoral immune responses, enhancing CD8 + T activation (Davar et al. 2021).”
Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy
Almonte, A. A., & Zitvogel, L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011540 · Cited by 9
Guardamagna, M., Berciano‐Guerrero, M., Lavado-Valenzuela, R., Auclin, É., Onieva-Zafra, J. L., Plaza-Andrades, I. J., Oliver, J., Garrido-Aranda, A., Pérez-Ruiz, E., Álvarez, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11054-2 · Cited by 10
“…found that the most enriched taxa associated with response included families Lachnospiraceae and Ruminococcaceae , as well as Bifidobacteriaceae and Coriobacteriaceae , thus further supporting the role of specific gut microbiota profiles in modulating treatment outcomes and prognosis 18 .”
Fecal microbiota transplantation: A promising treatment strategy for chronic liver disease
Ma, L., Zhang, M., Xu, Y., Hao, Y.-X., Niu, X.-X., Li, Y., & Xing, H. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i28.105089 · Cited by 13
Metabolism and epigenetics in cancer: toward personalized treatment
Zhang, X., Liu, D., Yin, S., Gao, Y., Li, X., & Wu, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530578 · Cited by 13
Akabane, M., Imaoka, Y., Lee, G. R., & Pawlik, T. M. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2568904 · Cited by 10
“While the association between gut microbiota composition or diversity and the therapeutic efficacy of anti-PD-1/PD-L1 antibodies has been well established in melanoma, similar findings have begun to emerge in HCC [82,83].”
Communication between gut microbiota-derived metabolites and the tumor microenvironment
Hu, X., Li, B., Li, Y., Liang, Y., & Huang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649438 · Cited by 11
Design and application of synthetic human gut microbial communities
Kim, M. S., & Bisanz, J. E. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2575923 · Cited by 10
“146 150-153 Informed by the RePOOPulate and related works, Nubiyota developed Microbial Ecosystem Therapeutic 4 (MET4), a defined consortium of 30 strains that includes taxa associated with ICI responsiveness.”
Chen, M., Zhou, J., Wu, C., Zhang, W., Long, F., Zhou, S.-S., Xu, J., Wu, J., Zou, Y., Li, S., et al. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123136 · Cited by 9
Wang, X., Wu, C., & Wei, H. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0039 · Cited by 9
“…for patients with melanoma in Israel and the United States reported that transplanting the gut microbiota from responders to nonresponders can activate CD8 + T cells and the corresponding immune cascade in the recipients’ tumor microenvironment (TME) (Baruch et al, 2021; Davar et al, 2021).”
The gut wall's potential as a partner for precision oncology in immune checkpoint treatment.
Lopez, S. H., Jalving, M., Fehrmann, R., Nagengast, W., de Vries, E. D., & de Haan, J. D. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102406 · Cited by 8
Kakish, H. H., Ahmed, F. A., Elshami, M., Loftus, A. W., Hoehn, R. S., Ammori, J. B., Ocuin, L. M., Winter, J. M., Bordeaux, J. S., Mangla, A., et al. (2022) · Cancers · doi:10.3390/cancers14215184 · Cited by 10
“Beyond these, new insights are evolving in the use of other oncolytic virotherapies [60], innate immunotherapies, gene-based targeted therapies, micro RNA therapies [61], PARP inhibitors [62], the fecal microbiome [63], and more.”
BackgroundDazio, G., Epistolio, S., Frattini, M., & Saletti, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247523 · Cited by 11
“Recently, a small study conducted in treatment-refractory melanoma showed efficacy of fecal microbiota transplantation in reprogramming the tumor microenvironment, leading to increased cancer immunogenicity [229].”
BackgroundRole of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer
Shi, L., Xu, Y., & Feng, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07689-0 · Cited by 9
“investigated the impact of gut microbiota on anti-PD-1 therapy in melanoma, showing that fecal microbiota transplantation (FMT) together with anti-PD-1 can expand the activated CD56+ CD8+ T cells and increase activation of CD8+ T and mucosal-associated invariant T (MAIT) cells in PBMCs to overcome resistance to anti-P…”
BackgroundDietary fungi in cancer immunotherapy: From the perspective of gut microbiota
Wei, Y., Song, D., Wang, R., Li, T., Wang, H., & Li, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1038710 · Cited by 9
“, evaluated the therapeutic efficiency of combined treatment of FMT (from PD-1 responders) and anti-PD-1 administration on patients with PD-1 refractory melanoma (82).”
BackgroundSelf-citationNeoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest
Kim, L., Coman, M., Pusztai, L., & Park, T. S. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13714-x · Cited by 9
Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
Gabrielli, G., Shouval, R., Ghilardi, G., van den Brink, M. R. M., & Ruella, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000950 · Cited by 11
Verhoef, J. I., Klont, E., van Overveld, F. J., & Rijkers, G. T. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2262765 · Cited by 9
“The first clinical studies demonstrating the positive effects of FMT on the outcome of ICI therapy in cancer have been performed in refractory metastatic melanoma patients [63,64].”
BackgroundLiu, B., Liu, Z., Jiang, T., Gu, X., Yin, X., Cai, Z., Zou, X., Dai, L., & Zhang, B. (2024) · European journal of medical research · doi:10.1186/s40001-024-01741-7 · Cited by 13
“Fecal Microbiota Transplantation (FMT), an approach to modulate gut microbiota, has been shown to increase ICIs efficacy in melanoma patients [75, 76], and emerging evidence has demonstrated the mitigation of ICIs-related colitis through FMT in clinical practice [77].”
BackgroundMining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
Li, B., Gong, T., Hao, Y., Zhou, X., & Cheng, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721249 · Cited by 9
“A coinciding immune activity after the FMT was found in blood and tumor microenvironment (100).”
BackgroundSakai, S. A., Aoshima, M., Sawada, K., Horasawa, S., Yoshikawa, A., Fujisawa, T., Kadowaki, S., Denda, T., Matsuhashi, N., Yasui, H., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.925444 · Cited by 13
“In addition, studies on fecal microbiota transplantation from responders to ICI therapy to non-responders showed a significant response (Baruch et al., 2021; Davar et al., 2021).”
BackgroundKurzhals, J. K., Klee, G., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810723 · Cited by 9
“However, given evidence that the gastrointestinal microbiome modulated the efficacy of immunotherapy, clinicians should remain judicious in the use of antibiotics prior to and concurrently with immunotherapy [8,34,40,46,47].”
BackgroundVihinen, H., Jokinen, A., Laajala, T. D., Wahid, N., Peltola, L., Kettunen, T., Rönkä, A., Tiainen, L., Skyttä, T., Kohtamäki, L. M., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.01.004 · Cited by 11
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.